The Longevity Boom Has a Blind Spot, and It’s Costing Consumers Billions

Panos Papadiamantis is founder and CPO of PNOĒ, a Y Combinator-backed metabolic health technology trusted by UCLA, MIT, and Red Bull.

A recent McKinsey survey found that 84% of U.S. consumers now consider wellness a top or important life priority, with annual spending in the U.S. alone exceeding $500 billion. Younger generations are leading the charge - Gen Z and millennials account for over 41% of wellness spending despite representing just 36% of the adult population. The money is flowing into supplements, peptide therapies, GLP-1 medications, IV drips, functional nutrition, and longevity protocols at an unprecedented rate.

Yet McKinsey's own research surfaces an uncomfortable paradox: the generations spending the most on wellness are simultaneously reporting worse mental health outcomes and greater struggles with basic health maintenance than older cohorts. More money in, but not necessarily better results out.

After years of building metabolic assessment technology and working with thousands of health professionals, I believe the core issue isn't what people are buying. It's that almost nobody measures whether it's working.

A trillion-dollar guessing game

The longevity market has exploded with interventions that promise biological optimization -from creatine and NMN to BPC-157, MOTS-c, and growth-hormone secretagogues. Each has varying degrees of scientific support. But the way consumers adopt them follows a remarkably consistent pattern: read about a compound, order it, take it for months, and evaluate progress based on how they feel.

Feeling is not measuring. Someone taking a peptide to improve recovery has no way to know if their cardiovascular system is actually delivering more oxygen to tissue. Someone spending hundreds on mitochondrial support supplements can't verify whether their mitochondria are producing energy more efficiently. Someone on a GLP-1 medication may be losing weight but has no insight into whether that weight loss is coming from fat or from the lean muscle mass that protects long-term metabolic health.

The tools to answer these questions exist. Cardiopulmonary exercise testing can quantify VO2 max - which a landmark JAMA Network Open study of 122,007 adults identified as one of the most powerful predictors of survival, outperforming smoking, diabetes, and hypertension as a mortality risk factor. Breath-based metabolic analysis can measure resting metabolic rate, fat-versus-carbohydrate utilization, and metabolic flexibility in a single session. These aren't experimental technologies. They've been the gold standard in clinical exercise physiology for decades.

What's changed is accessibility. These assessments are moving out of university labs and into wellness clinics, gyms, and longevity practices -making it possible for the first time to pair consumer-grade enthusiasm with clinical-grade data.

Why interventions fail without baselines

The distinction between supplements and peptides matters less than most people think. Supplements provide raw biological materials. Peptides deliver signaling instructions -telling cells to repair tissue, release hormones, or activate specific metabolic pathways. Both sound compelling on paper. But neither can override a system that isn't functioning well enough to respond.

A peptide signaling tissue repair requires adequate blood flow to deliver repair materials. A supplement supporting mitochondrial function has limited impact if your mitochondria are already strained by poor metabolic flexibility. A GLP-1 drug that suppresses appetite still needs a training and nutrition strategy to preserve muscle during weight loss.

In my experience, the practitioners who get the best patient outcomes aren't the ones using the most advanced interventions. They're the ones who measure first, address foundational gaps in cardiovascular fitness and metabolic efficiency, and only then layer targeted protocols on top -with data to track whether those protocols actually move the needle.

What the evidence-based path looks like

The British Journal of Sports Medicine published a 2025 systematic review confirming that cardiorespiratory fitness remains a stronger predictor of mortality than body weight -even after controlling for age, sex, and chronic disease. Every one-MET improvement in fitness, roughly equivalent to a 3.5 ml/kg/min gain in VO2 max, is associated with an 11–15% reduction in all-cause mortality risk.

That finding has a practical implication the wellness industry largely ignores: for many consumers, the single highest-return investment isn't a supplement, a peptide, or even a medication. It's structured exercise guided by objective metabolic data -knowing their actual heart rate zones, their fat-burning efficiency, and their aerobic ceiling rather than relying on generic formulas.

This doesn't mean supplements or peptides are worthless. It means they belong later in the sequence -after you know what your body actually needs, and after you've built the metabolic foundation that allows those interventions to work.

The market opportunity in measurement

For health and wellness businesses, the implication is strategic. The market is saturated with products. It is not saturated with objective assessment. Practitioners and companies that anchor their services in measurable outcomes -rather than selling the same supplements, peptides, and protocols as everyone else -build deeper trust, stronger retention, and a defensible market position.

Consumers are spending more than ever. They deserve to know if it's working.

Related Stories